<DOC>
	<DOC>NCT02147899</DOC>
	<brief_summary>The purpose of this research study is to test the safety and effectiveness of the oral investigational new drug, SYM-1219, for the treatment of bacterial vaginosis.</brief_summary>
	<brief_title>A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<criteria>Are females at least 18 years of age in good general health who are not menopausal. Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria: Offwhite (milky or gray), thin, homogeneous vaginal discharge Vaginal pH ≥ 4.7 Presence of clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount A positive 10% KOH Whiff test. Have a Gram stain slide Nugent score ≥ 4 at the Baseline visit (Day 1) Are pregnant, lactating, or planning to become pregnant during the study. Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex. Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline visit (Day 1).</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>